This study found that higher levels of galectin-3 were associated with worse clinical outcomes in patients with CAD, suggesting that galectin-3 could be a valuable biomarker for identifying patients at increased risk for adverse events as elevated galectin-3 levels may indicate increased myocardial stress and remodeling, which are critical factors in the progression of heart disease. The gene discussed is LGALS3; the disease is coronary artery disorder.